As the RNAi-based therapeutics space becomes increasingly crowded, keeping track of who's doing what and when can prove a challenge. As such, RNAi News has compiled a list of the major players in the space and where their publicly stated clinical-development efforts stand.

For the most part, the timelines provided are unchanged from those provided by the companies in recent months. There are a few exceptions, however.